Applied Therapeutics Management
Management criteria checks 2/4
Applied Therapeutics' CEO is Les Funtleyder, appointed in Nov 2023, has a tenure of 1.08 years. directly owns 0.078% of the company’s shares, worth $79.57K. The average tenure of the management team and the board of directors is 1 years and 6.7 years respectively.
Key information
Les Funtleyder
Chief executive officer
US$675.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.08% |
| Management average tenure | 1yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Nov 15
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Applied Therapeutics to resume galactosemia study for AT-007
Feb 02Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling
Nov 24
Applied Therapeutics EPS misses by $0.21
Nov 12CEO
Les Funtleyder (54 yo)
1.1yrs
Tenure
US$675,150
Compensation
Mr. Les D. Funtleyder is the Interim Chief Executive Officer of Applied Therapeutics, Inc. since December 20, 2024. He is Independent Director of Reviva Pharmaceuticals Holdings, Inc. since December 8, 202...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interm CEO | 1.1yrs | US$675.15k | 0.078% $ 79.6k | |
| Founder | no data | US$9.49m | 3.91% $ 4.0m | |
| Chief Medical Officer | 6.3yrs | US$3.04m | 0.14% $ 148.2k | |
| Executive Chairman | no data | no data | no data | |
| COO & Chief Business Officer | less than a year | no data | no data | |
| Chief Accounting Officer | 1.5yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
1.0yrs
Average Tenure
58yo
Average Age
Experienced Management: APLT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interm CEO | 8.5yrs | US$675.15k | 0.078% $ 79.6k | |
| Founder | 8.9yrs | US$9.49m | 3.91% $ 4.0m | |
| Executive Chairman | no data | no data | no data | |
| Independent Director | 5.7yrs | US$92.53k | 0.017% $ 17.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Lead Independent Director | 7.8yrs | US$88.78k | 0.052% $ 53.2k | |
| Independent Director | 5.6yrs | US$94.40k | 0.054% $ 55.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.7yrs
Average Tenure
66.5yo
Average Age
Experienced Board: APLT's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:34 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Applied Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Carter Gould | Barclays |
| Catherine Seifert | CFRA Equity Research |